Acadia Trust Na Lowers stake in C R Bard Inc (BCR)

C R Bard Inc (BCR) : Acadia Trust Na reduced its stake in C R Bard Inc by 1.59% during the most recent quarter end. The investment management company now holds a total of 47,588 shares of C R Bard Inc which is valued at $10.4 Million after selling 769 shares in C R Bard Inc , the firm said in a disclosure report filed with the SEC on May 11, 2016.C R Bard Inc makes up approximately 3.35% of Acadia Trust Na’s portfolio.

Other Hedge Funds, Including , Mufg Americas Holdings Corp boosted its stake in BCR in the latest quarter, The investment management firm added 17 additional shares and now holds a total of 1,672 shares of C R Bard Inc which is valued at $365,583. C R Bard Inc makes up approx 0.01% of Mufg Americas Holdings Corp’s portfolio.Ifc Holdings Incorporatedfl reduced its stake in BCR by selling 75 shares or 4.3% in the most recent quarter. The Hedge Fund company now holds 1,670 shares of BCR which is valued at $361,388. C R Bard Inc makes up approx 0.05% of Ifc Holdings Incorporatedfl’s portfolio.Rhumbline Advisers boosted its stake in BCR in the latest quarter, The investment management firm added 6,392 additional shares and now holds a total of 126,994 shares of C R Bard Inc which is valued at $27.5 Million. C R Bard Inc makes up approx 0.09% of Rhumbline Advisers’s portfolio.Hl Financial Services reduced its stake in BCR by selling 1,237 shares or 4.34% in the most recent quarter. The Hedge Fund company now holds 27,279 shares of BCR which is valued at $5.8 Million. C R Bard Inc makes up approx 0.14% of Hl Financial Services’s portfolio.

C R Bard Inc opened for trading at $218.54 and hit $223.02 on the upside on Monday, eventually ending the session at $221.91, with a gain of 1.49% or 3.26 points. The heightened volatility saw the trading volume jump to 4,92,981 shares. Company has a market cap of $16,270 M.

On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.

Many Wall Street Analysts have commented on C R Bard Inc. Company shares were Reiterated by Barclays on Apr 28, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 212 from a previous price target of $195 .C R Bard Inc was Initiated by Nomura to “Neutral” on Mar 17, 2016.

C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.

Leave a Reply

C R Bard Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on C R Bard Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.